RecruitingPHASE2INTERVENTIONAL

Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

This research is looking into a new nasal spray called ETH47. It's for people who have asthma. The main goal is to find out if this spray can help stop asthma symptoms from getting worse or even appearing after someone catches a common cold, which is often caused by a rhinovirus. Scientists want to see if ETH47 can make a difference in how people with asthma react to these common viruses. The study is in its early stages (Phase IIa), meaning they are checking if the treatment is safe and if it shows promise. Participants will receive either the active spray (ETH47) or a dummy spray (placebo) and will be monitored closely.

At a glance

Status

Recruiting

Phase

PHASE2

Sponsor

Ethris GmbH

Enrolment target

Start

24 Jun 2025

Estimated completion

01 Jun 2026

Asthma (Diagnosis)

What is this study about?

This study is trying to understand how a new nasal spray, ETH47, might help people with asthma. We know that common colds, often caused by a virus called rhinovirus, can trigger asthma symptoms and make them worse. This research is designed to see if using ETH47 as a nasal spray can reduce or even prevent these asthma-related problems when someone is exposed to the cold virus.

The researchers will closely watch how participants' asthma symptoms develop after they are intentionally exposed to a small amount of rhinovirus in a controlled setting. This isn't to make people sick, but to carefully observe the effects of the virus and see if the new spray can offer protection compared to a placebo (a spray with no active medicine).

Finding new ways to manage asthma, especially when cold viruses are involved, is very important. If ETH47 proves to be helpful, it could potentially offer a new treatment option for people whose asthma is often made worse by common infections like the cold.

Key takeaways

New nasal spray (ETH47) being tested for asthma.
Aims to reduce asthma symptoms triggered by common colds.
Compares ETH47 to a dummy spray (placebo).
Involves safe, controlled exposure to a cold virus.
Looking for adults aged 18-65 with stable asthma.
Participation helps advance asthma research.

Who may be eligible?

To join this study, you need to be an adult with asthma, aged between 18 and 65. Your asthma should be clearly diagnosed, and you should be on stable asthma medication (like inhaled steroids or a combination of inhaled steroids and long-acting bronchodilators) for at least three months. It's important that your asthma has been stable, meaning you haven't had any severe flare-ups requiring extra care in the last three months, and you haven't had any cold symptoms recently.

There are also some reasons why you might not be able to join. For example, if you've had a cold recently, or if you also suffer from conditions like allergic rhinitis, chronic sinusitis, or nasal polyps. People with other serious lung conditions like COPD or emphysema are also not suitable for this study. If you smoke or used to smoke within the last year, or have a long history of smoking, you likely won't be able to take part. Researchers also need to make sure you're generally healthy enough for the study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 18 and 65 years old?
Do you have a diagnosis of asthma?
Has your asthma medication been stable for at least 3 months?
Have you been free from asthma flare-ups for at least 3 months?
Have you had no cold symptoms in the last month?
Do you not smoke or have you not smoked in the last year?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you might receive either the new nasal spray (ETH47) or a placebo (a dummy spray). You won't know which one you're getting. The study will involve several visits to the clinic so doctors can monitor your health and asthma symptoms closely. A key part of the study involves being exposed to a common cold virus (rhinovirus) in a controlled way, so the researchers can observe how your body reacts and if the spray helps. There will be careful follow-up appointments to check on you after the virus exposure. The total duration of your participation in the study, including all visits and follow-up, will be explained fully by the study team.

Potential risks and benefits

Participating in this study might offer you some potential benefits, such as contributing valuable information to asthma research and potentially helping to find new treatments. You would also receive close medical attention throughout the study. However, there are also potential risks; for example, being exposed to the cold virus means you might develop cold symptoms, and there could be unknown side effects from the study medication, although early studies suggest it's safe. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (2)

Imperial College Healthcare NHS Trust
Verified postcode
London, United Kingdom· Recruiting
Medicines Evaluation Unit Limited
Verified postcode
Manchester, United Kingdom· Recruiting

Common questions

What is ETH47?

ETH47 is a new nasal spray being tested to see if it can help people with asthma when they catch a common cold.

Why am I being exposed to a cold virus?

Researchers will safely expose you to a cold virus in a controlled way to see if the nasal spray helps prevent your asthma symptoms from getting worse.

Will I get sick from the cold virus?

You might develop mild cold symptoms, but you will be closely monitored by medical staff throughout the study.

What are 'stable asthma' medications?

This means your asthma medicine (like inhalers) and their doses haven't changed for at least three months before the study starts.

Can I still take part if I'm a smoker?

Generally no, if you currently smoke, or have smoked in the last year, you are unlikely to be able to take part. Vapers may be included if they agree to stop before starting the study.

How to find out more

Dr. Philipp Schreppel

schreppel@ethris.com +4989244153042 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.